Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease
HanAll Biopharma and Daewoong Pharmaceutical announced that they have entered into a co-development agreement with NurrOn […]
Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes
The research results of a Daewoong Pharmaceutical SGLT-2 inhibitor new drug for diabetes, ‘Envlo’, have been […]
Daewoong Pharmaceutical Begins the First Administration of the Bersiporocin, a New Treatment for Idiopathic Pulmonary Fibrosis
The world’s first-in-class candidate substance against idiopathic pulmonary fibrosis, ‘Bersiposocin‘ (DWN12088), which is under the […]
Daewoong Pharmaceutical Submitted NDA for its Global New Drug Fexuclue in 11 Countries
Fexuclue from Daewoong Pharmaceutical is attracting attention as a game changer in the global gastroesophageal […]
- Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
- Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
- Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
- Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more